Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL75770 | 0.86 | KDM4E (0.45) | POLBL3MBTL1KDM4EALDH1A1MAPT | |
| SCHEMBL73678 | 0.83 | NPC1 (0.38) | POLBL3MBTL1NPSR1KDM4EALDH1A1 | |
| SCHEMBL7509825 | 0.81 | FAAH (0.38) | L3MBTL1KDM4EALDH1A1MAPTHSD17B10 | |
| SCHEMBL8341632 | 0.80 | POLB (0.52) | POLBL3MBTL1NPSR1KDM4EALDH1A1 | |
| SCHEMBL28242652 | 0.80 | — | — | |
| SCHEMBL24997068 | 0.80 | POLB (0.52) | POLBL3MBTL1NPSR1KDM4EALDH1A1 | |
| SCHEMBL10464787 | 0.80 | FAAH (0.41) | L3MBTL1KDM4EHSD17B10 | |
| SCHEMBL7505022 | 0.80 | FAAH (0.41) | L3MBTL1KDM4EHSD17B10 | |
| SCHEMBL3549851 | 0.78 | PIK3CD (0.32) | KDM4EHSD17B10 | |
| SCHEMBL3548641 | 0.77 | SMO (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 204 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024051766-A1 | MOLECULAR GLUE COMPOUND BASED ON CEREBLON PROTEIN DESIGN AND USE THEREOF | 标新生物医药科技(上海)有限公司 | 2024-03-14 | — | — | WO | claimed |
| EP-3704102-B1 | SUBSTITUTED QUINOLINE ANALOGS AS ALDEHYDE DEHYDROGENASE 1A1 (ALDH1A1) INHIBITORS | US HEALTH (US) | 2024-02-28 | — | — | EP | claimed |
| CN-115232118-A | Protein kinase inhibitory activity small molecule and derivative thereof, preparation method, pharmaceutical composition and application | 中国药科大学 | 2022-10-25 | — | — | CN | claimed |
| US-20220143002-A1 | SULFUR-CONTAINING COMPOUND BASED ON GLUTARIMIDE SKELETON AND APPLICATION THEREOF | SHANGHAITECH UNIVERSITY (CN) | 2022-05-12 | — | — | US | claimed |
| EP-3932922-A1 | SULFUR-CONTAINING COMPOUND BASED ON GLUTARIMIDE SKELETON AND APPLICATION THEREOF | ShanghaiTech University (CN) | 2022-01-05 | — | — | EP | claimed |
| US-20170152269-A1 | FUSED BICYCLIC COMPOUNDS AND THEIR USE AS CDK INHIBITORS | ANONCO SCIENCES, INC. (US) | 2017-06-01 | — | — | US | claimed |
| EP-2091926-B1 | SUBSTITUTED PYRAZOLE AND TRIAZOLE COMPOUNDS AS KSP INHIBITORS | NOVARTIS AG (CH) | 2015-10-21 | — | — | EP | claimed |
| US-9096546-B2 | Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin | ALBANY MOLECULAR RESEARCH, INC. (US) | 2015-08-04 | — | — | US | claimed |
| US-9045468-B2 | 2,5-methano- and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin | ALBANY MOLECULAR RESEARCH, INC. (US) | 2015-06-02 | — | — | US | claimed |
| US-8987252-B2 | Aryloxy- and heteroaryloxy-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin | ALBANY MOLECULAR RESEARCH, INC. (US) | 2015-03-24 | — | — | US | claimed |
| US-20040029898-A1 | Substituted quinolines as antitumor agents | ASTRAZENECA AB (SE) | 2004-02-12 | — | — | US | claimed |
| JP-2004502763-A | — | — | 2004-01-29 | — | — | JP | claimed |
| US-20030225097-A1 | Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by np y5 receptor | ASTRAZENECA AB (SE) | 2003-12-04 | — | — | US | claimed |
| US-20030216406-A1 | Pyrimidine derivatives | ASTRAZENECA AB (SE) | 2003-11-20 | — | — | US | claimed |
| EP-1337524-A1 | SUBSTITUTED QUINOLINES AS ANTITUMOR AGENTS | AstraZeneca AB (SE) | 2003-08-27 | — | — | EP | claimed |
| EP-1303496-A1 | PYRIMIDINE DERIVATIVES | AstraZeneca AB (SE) | 2003-04-23 | — | — | EP | claimed |
| EP-1278739-A1 | AMINO SUBSTITUTED DIBENZOTHIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS MEDIATED BY THE NP Y5 RECEPTOR | AstraZeneca AB (SE) | 2003-01-29 | — | — | EP | claimed |
| WO-2002044166-A1 | SUBSTITUTED QUINOLINES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2002-06-06 | — | — | WO | claimed |
| WO-2002004429-A1 | PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-01-17 | — | — | WO | claimed |
| WO-2001085714-A1 | AMINO SUBSTITUTED DIBENZOTHIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS MEDIATED BY THE NP Y5 RECEPTOR | ASTRAZENECA AB (SE) | 2001-11-15 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029898-A1 | Substituted quinolines as antitumor agents | NQO2, NQO1, TP53 | POLB 2116/4885L3MBTL1 4744/4885NPSR1 1586/4885 |
| US-20030225097-A1 | Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by np y5 receptor | NPY5R, NPY1R, NPY2R | POLB 4332/4885L3MBTL1 1377/4885NPSR1 8/4885 |
| US-20170152269-A1 | FUSED BICYCLIC COMPOUNDS AND THEIR USE AS CDK INHIBITORS | CDK2, CDK1, CDK9 | POLB 489/4885L3MBTL1 1133/4885NPSR1 4429/4885 |
| US-20220143002-A1 | SULFUR-CONTAINING COMPOUND BASED ON GLUTARIMIDE SKELETON AND APPLICATION THEREOF | GLS, SQOR, GCDH | POLB 3067/4885L3MBTL1 2098/4885NPSR1 3238/4885 |
| US-20030216406-A1 | Pyrimidine derivatives | TYMP, TYMS, CCNT1 | POLB 50/4885L3MBTL1 2158/4885NPSR1 2794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.